# MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma

> **NCT02399189** · PHASE2 · UNKNOWN · sponsor: **Jun Zhu** · enrollment: 39 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** R-MT followed by auto-HSCT

## Key facts

- **NCT ID:** NCT02399189
- **Lead sponsor:** Jun Zhu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-05
- **Primary completion:** 2017-04
- **Final completion:** 2019-04
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2015-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02399189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02399189, "MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02399189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*